We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The State Drug Administration of China (SDA) announced in the evening of May 29, 2018 the decision to revise the package insert of Bupleurum injection (as shown in the following figure).